MX2016007795A - Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales. - Google Patents

Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales.

Info

Publication number
MX2016007795A
MX2016007795A MX2016007795A MX2016007795A MX2016007795A MX 2016007795 A MX2016007795 A MX 2016007795A MX 2016007795 A MX2016007795 A MX 2016007795A MX 2016007795 A MX2016007795 A MX 2016007795A MX 2016007795 A MX2016007795 A MX 2016007795A
Authority
MX
Mexico
Prior art keywords
pelvi
treating
preventing
antagonists
pathological conditions
Prior art date
Application number
MX2016007795A
Other languages
English (en)
Other versions
MX370061B (es
Inventor
Le Grand Bruno
Junquero Didier
MONJOTIN Nicolas
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2016007795A publication Critical patent/MX2016007795A/es
Publication of MX370061B publication Critical patent/MX370061B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere al uso de antagonistas del PAR1, en particular de vorapaxar, de atopaxar y de 3- (2-cloro-fenil) -1- [4- (4-fluoro-bencil)piperazin-1-il] propenona, o una sal farmacéuticamente aceptable sal de los mismos, para prevenir y/o tratar condiciones patológicas funcionales pelviperineales y, más particularmente, el síndrome de vejiga dolorosa.
MX2016007795A 2013-12-16 2014-10-31 Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales. MX370061B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1362682A FR3014693B1 (fr) 2013-12-16 2013-12-16 Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
PCT/EP2014/073453 WO2015090705A1 (fr) 2013-12-16 2014-10-31 Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales

Publications (2)

Publication Number Publication Date
MX2016007795A true MX2016007795A (es) 2016-09-07
MX370061B MX370061B (es) 2019-11-29

Family

ID=50424483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007795A MX370061B (es) 2013-12-16 2014-10-31 Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales.

Country Status (16)

Country Link
US (2) US9980970B2 (es)
EP (1) EP3082818A1 (es)
JP (1) JP6612233B2 (es)
KR (1) KR20160089518A (es)
CN (1) CN105813642B (es)
AU (1) AU2014365665B2 (es)
CA (1) CA2931161A1 (es)
FR (1) FR3014693B1 (es)
IL (1) IL246216A0 (es)
MA (1) MA39072A1 (es)
MX (1) MX370061B (es)
RU (1) RU2678309C1 (es)
SA (1) SA516371348B1 (es)
TN (1) TN2016000196A1 (es)
UA (1) UA120603C2 (es)
WO (1) WO2015090705A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3090317B1 (fr) * 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110393718B (zh) * 2019-08-20 2022-10-04 青岛海洋生物医药研究院 阿托帕沙溴酸作为新型jak-stat3信号通路抑制剂的用途和研究方法
FR3109089B1 (fr) * 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982984B1 (en) 2002-04-16 2013-02-13 Merck Sharp & Dohme Corp. Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them
US8440627B2 (en) * 2004-11-04 2013-05-14 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
FR2902426B1 (fr) * 2006-06-19 2008-09-05 Pierre Fabre Medicament Sa Derives de cinnamoyl-piperazine
CA2834621A1 (en) * 2011-05-12 2012-11-15 Universite Laval Par1 inhibitors for use in the treatment or prevention of paramyxoviridae infections
RU2468759C1 (ru) * 2011-09-23 2012-12-10 Ольга Викторовна Тарабанова Способ лечения нарушений анатомических соотношений органов малого таза у женщин с атрофией мышц, поднимающих задний проход, и/или множественными дефектами ректо-вагинальной фасции

Also Published As

Publication number Publication date
CN105813642B (zh) 2019-05-03
MA39072A1 (fr) 2017-05-31
EP3082818A1 (fr) 2016-10-26
UA120603C2 (uk) 2020-01-10
US9980970B2 (en) 2018-05-29
TN2016000196A1 (fr) 2017-10-06
US20180311253A1 (en) 2018-11-01
AU2014365665B2 (en) 2019-08-29
US20160287603A1 (en) 2016-10-06
KR20160089518A (ko) 2016-07-27
JP6612233B2 (ja) 2019-11-27
FR3014693B1 (fr) 2016-01-08
RU2678309C1 (ru) 2019-01-25
AU2014365665A1 (en) 2016-07-14
IL246216A0 (en) 2016-07-31
SA516371348B1 (ar) 2019-11-10
US10265322B2 (en) 2019-04-23
WO2015090705A1 (fr) 2015-06-25
FR3014693A1 (fr) 2015-06-19
MX370061B (es) 2019-11-29
JP2016540799A (ja) 2016-12-28
CA2931161A1 (fr) 2015-06-25
CN105813642A (zh) 2016-07-27
HK1221913A1 (zh) 2017-06-16

Similar Documents

Publication Publication Date Title
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
PT2945642T (pt) Proteína do fator 1 para utilização no tratamento ou prevenção de doenças
HK1223319A1 (zh) 用於治疗或预防眼科病的方法
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
WO2012158672A3 (en) Compounds for use in treatment of mucositis
PE20151526A1 (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
ZA201508050B (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
WO2014140856A3 (en) Mir-142 and antagonists thereof for treating disease
AU2014365665A1 (en) Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
PH12018500579A1 (en) Fungal keratitis prophylactic or therapeutic agent
IN2013MU03428A (es)
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
ZA201600894B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes

Legal Events

Date Code Title Description
FG Grant or registration